Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer

Inclusion Criteria:

* Histologically proven NSCLC (
* Mutational status of EGFR : wild type or unknown
* Stage IV disease with cytologic or histologic documentation in patients with a single easily accessible metastasis or metastatic relapses in a non irradiated region from a primary tumor treated with surgery or radiotherapy (with cytologic or histologic documentation of relapse)
* Presence of at least one measurable target lesion (one dimension) in a non irradiated region (at least 10 mm on spiral computed tomography).
* Age ≥ 18 years
* Performance status 0,1,2 exception : age \> 74 years only PS 0 or 1
* Normal hepatic function
* Normal renal function
* Normal calcemia
* Normal haematological function
* Life expectancy \> 12 weeks.
* Women of child bearing potential must use effective contraception.
* Men might be surgically sterile or accept to use an effective contraceptive procedure during and until 6 months after the treatment.
* Written informed consent to participate in the study.

Exclusion Criteria:

* PS \> 2, exception : age \> 74 years only PS ≥ 2
* Presence of another cancer
* Previous treatment with an anti egfr agent or docetaxel
* QT prolongation (\>470 ms)
* Uncontrolled arterial hypertension.
* Concurrent radiotherapy, except for palliative bone irradiation.
* Stroke less than 6 months before study entry.
* Psychiatric or neurological disorders preventing the patient from understanding the nature of the trial
* Uncontrolled infection.
* Caval syndrome
* Other organic disorders preventing inclusion in the trial
* Malabsorption syndrome
* Allergy to erlotinib or one of its constituents
* Allergy to docetaxel or one of its constituents
* Pregnancy and breast-feeding
* Surgery less than two months before study entry